A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang; Robert Orlowski; Xiaowei Xu; Rosemarie Mick; Sangeeth M. George; Patrick Yan; Sasikanth Manne; Adam Kraya; Bradley Wubbenhorst; Liza M. Dorfman; Kurt D’Andrea; Brandon M. Wenz; Shujing Liu; Lakshmi Chilukuri; Andrew Kozlov; Mary Carberry; Lydia Giles; Melanie Wain Kier; Felix Quagliarello; Suzanne McGettigan; Kristin Kreider; Lakshmanan Annamalai; Qing Zhao; Robin Mogg; Wei Xu; Wendy M. Blumenschein; Jennifer H. Yearley; Gerald P. Linette; Ravi K. Amaravadi; Lynn M. Schuchter; Ramin S. Herati; Bertram Bengsch; Katherine L. Nathanson; Michael D. Farwell; Giorgos C. Karakousis; E. John Wherry; Tara C. Mitchell

doi:10.1038/s41591-019-0357-y

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang(Parker Institute for Cancer Immunotherapy), Robert Orlowski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaowei Xu(University of Pennsylvania), Rosemarie Mick(Parker Institute for Cancer Immunotherapy), Sangeeth M. George(Bristol-Myers Squibb (United States)), Patrick Yan(Translational Therapeutics (United States)), Sasikanth Manne(Translational Therapeutics (United States)), Adam Kraya(University of Pennsylvania), Bradley Wubbenhorst(University of Pennsylvania), Liza M. Dorfman(University of Pennsylvania), Kurt D’Andrea(University of Pennsylvania), Brandon M. Wenz(University of Pennsylvania), Shujing Liu(University of Pennsylvania), Lakshmi Chilukuri(Translational Therapeutics (United States)), Andrew Kozlov(University of Pennsylvania), Mary Carberry(University of Pennsylvania), Lydia Giles(University of Pennsylvania), Melanie Wain Kier(University of Pennsylvania), Felix Quagliarello(Stemcell Technologies), Suzanne McGettigan(University of Pennsylvania), Kristin Kreider(University of Pennsylvania), Lakshmanan Annamalai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qing Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Xu(University of Pennsylvania), Wendy M. Blumenschein(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gerald P. Linette(Parker Institute for Cancer Immunotherapy), Ravi K. Amaravadi(University of Pennsylvania), Lynn M. Schuchter(University of Pennsylvania), Ramin S. Herati(University of Pennsylvania), Bertram Bengsch(University Medical Center Freiburg), Katherine L. Nathanson(Parker Institute for Cancer Immunotherapy), Michael D. Farwell(University of Pennsylvania), Giorgos C. Karakousis(University of Pennsylvania), E. John Wherry(Parker Institute for Cancer Immunotherapy), Tara C. Mitchell(University of Pennsylvania)

Nature Medicine

February 25, 2019

10.1038/s41591-019-0357-y

Cited by 698

Abstract

Related Papers

No related papers found

Powered by citation graph analysis